Atay VURAL, Aslı TUNCER KURNE, Rana KARABUDAK

Multipl Sklerozisin İmmünpatogenezi Kısım 2: Hastalığın doğuşu ve yükselişi

Immünopathogenenis of Multiple Sclerosis Part 2: The beginning and rise of the disease

In the first part of this review, we described that plaques that we see on MRI are not all the same, there are different plaque patterns between patients and although we cannot detect with conventional MRI, there are cortical plaques in almost all of the patients. In the second part, we will first concentrate on the first phase of disease. We will explain the data that we learned by in vivo imaging of animal models. Thereafter, we will review what we have learned from conventional and non-conventional MRI imaging, and discuss the shortcomings of these methods. After the completion of this section, we hope that readers will have knowledge on the mechanisms of some of the most widely used therapeutic agents and will be able to interpret MR images of MS patients more efficiently.

PDF

___

1. Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 2009;9:393-407.
2. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006;129:1953-1971.
3. Pachter JS, de Vries HE, Fabry Z. The blood-brain barrier and its role in immune privilege in the central nervous system. J Neuropathol Exp Neurol 2003;62:593-604.
4. Ransohoff RM. Immunology: In the beginning. Nature 2009;462:41-42.
5. Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 2009;10:514-523.
6. Bartholomaus I, Kawakami N, Odoardi F, et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 2009;462:94-98.
7. Moll NM, Cossoy MB, Fisher E, et al. Imaging correlates of leukocyte accumulation and CXCR4/CXCL12 in multiple sclerosis. Arch Neurol 2009;66:44-53.
8. Cruz-Orengo L, Holman DW, Dorsey D, et al. CXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunity. J Exp Med 2011;208:327- 339.
9. Nourshargh S, Hordijk PL, Sixt M. Breaching multiple barriers: leukocyte motility through venular walls and the interstitium. Nat Rev Mol Cell Biol 2010;11:366-378.
10. Lossinsky AS, Shivers RR. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Review. Histol Histopathol 2004;19:535-564.
11. Voskuhl RR, Peterson RS, Song B, et al. Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. J Neurosci 2009;29:11511-11522.
12. Steinman L. A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol 2009;9:440-447.
13. Chabas D, Baranzini SE, Mitchell D, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001;294:1731-1735.
14. Hur EM, Youssef S, Haws ME, Zhang et al. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol 2007;8:74-83.
15. Vogt MH, Lopatinskaya L, Smits M, et al. Elevated osteopontin levels in active relapsing-remitting multiple sclerosis. Ann Neurol 2003;53:819-822.
16. Shinohara ML, Kim JH, Garcia VA, et al. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity 2008;29:68-78.
17. Caillier S, Barcellos LF, Baranzini SE, et al. Osteopontin polymorphisms and disease course in multiple sclerosis. Genes Immun 2003;4:312-315.
18. Ousman SS, Tomooka BH, van Noort JM, et al. Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature 2007;448:474-479.
19. van Noort JM, van Sechel AC, Bajramovic JJ, et al. The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature 1995;375:798-801.
20. van Veen T, van Winsen L, Crusius JB, et al. [Alpha] B-crystallin genotype has impact on the multiple sclerosis phenotype. Neurology 2003;61:1245-1249.
21. Brex PA, Ciccarelli O, O'Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158-164. 22. Poloni G, Minagar A, Haacke EM, et al. Recent developments in imaging of multiple sclerosis. Neurologist 2011;17:185-204.
23. Cotton F, Weiner HL, Jolesz FA, et al. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003;60:640-646.
24. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a metaanalysis. Gadolinium MRI Meta-analysis Group. Lancet 1999;353:964-969.
25. Truyen L, van Waesberghe JH, van Walderveen MA, et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996;47:1469-1476.
26. van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1- weighted spin-echo MRI in multiple sclerosis. Neurology 1998;50:1282-1288.
27. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002;59:1412-1420.
28. Filippi M, Rocca MA, Martino G, et al. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol 1998;43:809-814.
29. Cercignani M, Bozzali M, Iannucci G, et al. Magnetisation transfer ratio and mean diffusivity of normal appearing white and grey matter from patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;70:311-317.
30. Tortorella C, Viti B, Bozzali M, et al. A magnetization transfer histogram study of normal-appearing brain tissue in MS. Neurology 2000;54:186-193.
31. Agosta F, Rovaris M, Pagani E, et al. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain 2006;129:2620-2627.
32. Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003;126:433-437.
33. De Stefano N, Matthews PM, Fu L, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998;121 ( Pt 8):1469-1477.
34. Iannucci G, Rovaris M, Giacomotti L, et al. Correlation of multiple sclerosis measures derived from T2-weighted, T1- weighted, magnetization transfer, and diffusion tensor MR imaging. AJNR Am J Neuroradiol 2001;22:1462-1467.
35. Filippi M, Rocca MA. MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system. J Neurol 2005;252 Suppl 5:v16-24.
36. Vellinga MM, Oude Engberink RD, Seewann A, et al. Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. Brain 2008;131:800-807.
37. Filippi M, Rocca MA, Barkhof F, et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol 2012;11:349-360.
38. Serres S, Mardiguian S, Campbell SJ, et al. VCAM-1-targeted magnetic resonance imaging reveals subclinical disease in a mouse model of multiple sclerosis. FASEB J 2011;25:4415-4422.
39. Grabner G, Dal-Bianco A, Schernthaner et al. Analysis of multiple sclerosis lesions using a fusion of 3.0 T FLAIR and 7.0 T SWI phase: FLAIR SWI. J Magn Reson Imaging 2011;33:543-549.
40. Lummel N, Boeckh-Behrens T, Schoepf V, et al. Presence of a central vein within white matter lesions on susceptibility weighted imaging: a specific finding for multiple sclerosis? Neuroradiology 2011;53:311-317.